Synonyms: BAY-2965501 | BAY2965501
Compound class:
Synthetic organic
Comment: BAY 2965501 is a potential first-in-class inhibitor of the atypical protein kinase C isoform protein kinase C zeta (PKCζ). It was developed for anti-tumour potential. The chemical structure was disclosed during the 'First Disclosures of New Drug Candidates' session at the April 2023 (Orlando) meeting of the AACR.
|
|
No information available. |
Summary of Clinical Use |
BAY 2965501 has progressed to early stage clinical evaluation. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT05614102 | A First-in-human Study to Learn How Safe the Study Treatment BAY2965501 is, to Find the Best Dose, How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, and How it Acts on Different Tumors in Participants With Advanced Solid Tumors | Phase 1 Interventional | Bayer |